Actively Recruiting
Belief Updating in Treatment Resistant Depression
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2026-04-13
60
Participants Needed
1
Research Sites
134 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Major depressive disorder (MDD) is characterized by a cognitive triad of negative beliefs about oneself, the future and the world. For example, depressed patients hold persistently negative expectations about the future, despite contradictory evidence, and these strong negative beliefs are thought to play an important role in the maintenance of depressive symptoms and potentially in treatment resistance. Indeed, one out of three patients with major depressive disorder does not respond to conventional, monoaminergic treatments, which has led to the concept of treatment resistant depression (TRD). It is unknown how the brain encodes the strong negative beliefs that are insensitive to positive disconfirming information in TRD patients, and how these neural underpinnings of maladaptive belief updating are altered by antidepressant treatment. The principal objective of this study is to gain insight into the brain mechanisms of belief updating about the future in TRD patients before and after starting ketamine treatment. The results of this study are expected to provide a better understanding of the neurocognitive mechanisms of belief-updating in depressed patients, and how these mechanisms contribute to clinical improvement following ketamine antidepressant treatment.
CONDITIONS
Official Title
Belief Updating in Treatment Resistant Depression
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 to 70 years
- Male or female
- Diagnosed with major depressive disorder (MDD) according to DSM-5 criteria
- Montgomery-Åsberg Depression Rating Scale (MADRS) score of 20 or higher
- Treatment resistant depression defined by failure to respond to at least two different antidepressant treatments
- Affiliated with a social security regime
- Starting a new antidepressant treatment involving glutamate receptor modulators
You will not qualify if you...
- Diagnosis of mental disorders other than MDD such as borderline personality disorder or schizophrenia
- Inability to understand or perform the behavioral task
- Mini Mental Score (MMS) of 25 or lower
- Current use of dopaminergic agonists or monoamine oxidase inhibitors (MAOI)
- Neurological disorders including epilepsy, brain tumor, or uncorrected visual or auditory deficits
- Contraindications for MRI such as metallic implants, pacemakers, vascular malformations, claustrophobia, or unwillingness to be informed of abnormal MRI findings
- Pregnancy
- Receiving state medical aid (AME)
- Under guardianship, curatorship, or legal protection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
GH Pitié Salpêtrière
Paris, France
Actively Recruiting
Research Team
P
Philippe FOSSATI, PUPH
CONTACT
L
Liane Schmidt, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here